AMPA receptor antagonist CFM-2 decreases survivin expression in cancer cells

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Domingo Sanchez Ruiz - , Ace Alzheimer Center Barcelona (Author)
  • Hella Luksch - , University Medicine (Faculty of Medicine and University Hospital), Department of Paediatrics, University Hospital Carl Gustav Carus Dresden (Author)
  • Marco Sifringer - , Charité – Universitätsmedizin Berlin (Author)
  • Achim Temme - , Department of Neurosurgery, TUD Dresden University of Technology (Author)
  • Christian Staufner - , Heidelberg University  (Author)
  • Wojciech Rzeski - , Maria Curie-Skłodowska University in Lublin, Witold Chodźki Institute of Rural Medicine (Author)
  • Jenny Marzahn - , TUD Dresden University of Technology (Author)
  • Aneta Grabarska - , Medical University of Lublin (Author)
  • Chrysanthy Ikonomidou - , University of Wisconsin-Madison (Author)
  • Andrzej Stepulak - , Medical University of Lublin (Author)

Abstract

Background: Glutamate receptors are widely expressed in different types of cancer cells. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors are ionotropic glutamate receptors which are coupled to intracellular signaling pathways that influence cancer cell survival, proliferation, and migration. Blockade of AMPA receptors by pharmacologic compounds may potentially constitute an effective tool in anticancer treatment strategies. Method: Here we investigated the impact of the AMPA receptor antagonist CFM-2 on the expression of the protein survivin, which is known to promote cancer cell survival and proliferation. We show that CFM-2 inhibits survivin expression at mRNA and protein levels and decreases the viability of cancer cells. Using a stably transfected cell line which overexpresses survivin, we demonstrate that over-expression of survivin enhances cancer cell viability and attenuates CFM-2–mediated inhibition of cancer cell growth. Result: These findings point towards suppression of survivin expression as a new mechanism contributing to anticancer effects of AMPA antagonists.

Details

Original languageEnglish
Pages (from-to)591-596
Number of pages6
JournalAnti-cancer agents in medicinal chemistry
Volume18
Issue number4
Publication statusPublished - 2018
Peer-reviewedYes

External IDs

PubMed 29493464

Keywords

Sustainable Development Goals

Keywords

  • AMPA glutamate receptor, Antagonist, Cancer, Cells, CFM-2, Ionotropic glutamate receptors, Survivin